Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics
BOLT Price/Volume Stats
| Current price | $1.11 | 52-week high | $2.03 |
| Prev. close | $1.16 | 52-week low | $0.84 |
| Day low | $1.10 | Volume | 122,400 |
| Day high | $1.20 | Avg. volume | 118,477 |
| 50-day MA | $1.21 | Dividend yield | N/A |
| 200-day MA | $1.12 | Market Cap | 42.32M |
BOLT Stock Price Chart Interactive Chart >
Bolt Biotherapeutics, Inc. (BOLT) Company Bio
Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.
Latest BOLT News From Around the Web
Below are the latest news stories about BOLT BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
Pacira Appoints Frank D. Lee as Chief Executive Officer-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (th |
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design and rationale to be presented at the 2023 San Antonio Breast Cancer Symposium on Wednesday, December 6 REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of |
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateBDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical efficacy and longer durability; FDA Orphan Drug Designation granted for the BDC-1001 in gastric cancersFirst patient administered BDC-3042 in a Phase 1/2 dose-escalation and expansion clinical studyCash balance of $141.4 million as of September 30, 2023 anticipated to fund key miles |
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceREDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14, 2023, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York, New York. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at |
BOLT Price Returns
| 1-mo | N/A |
| 3-mo | 0.91% |
| 6-mo | 13.27% |
| 1-year | -29.75% |
| 3-year | -95.41% |
| 5-year | N/A |
| YTD | -0.89% |
| 2023 | -13.85% |
| 2022 | -73.47% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...